A Multicenter Blinded Study Evaluating EGFR and KRAS Mutation Testing Methods in the Clinical Non–Small Cell Lung Cancer Setting—IFCT/ERMETIC2 Project Part 1
Michèle Beau‐Faller, Hélène Blons, Caroline Domerg et al. · Journal of Molecular Diagnostics · 2013
Cited by 35 works. doi:10.1016/j.jmoldx.2013.07.009 Open-access PDF
Authors
- Michèle Beau‐Faller
- Hélène Blons
- Caroline Domerg
- Dorota Gajda
- Nicolas Richard
- Fabienne Escande
- Jérôme Solassol
- Marc Guillaume Denis
- Anne Cayre
- Isabelle Nanni‐Metellus
- Sylviane Olschwang
- Sarab Lizard
- Fabienne Piard
- Jean‐Luc Prétet
- Florence de Fraipont
- Ivan Bièche
- Patricia de Crémoux
- Isabelle Rouquette
- Pierre‐Paul Bringuier
- Jean Mosser
References
- The Measurement of Observer Agreement for Categorical Data
- Weighted kappa: Nominal scale agreement provision for scaled disagreement or partial credit.
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Note on the Sampling Error of the Difference Between Correlated Proportions or Percentages
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- Assessing agreement on classification tasks: the kappa statistic
- Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
- Applied Mixed Models in Medicine
- A New Procedure for Assessing Reliability of Scoring EEG Sleep Recordings
- Rapid Polymerase Chain Reaction-Based Detection of Epidermal Growth Factor Receptor Gene Mutations in Lung Adenocarcinomas